Introduction
============

Today, breast cancer is the second leading cause of cancer-associated mortality in women in the United States ([@b1-ol-0-0-11406],[@b2-ol-0-0-11406]). It is reported that 1 in 8 women (13%) are expected to develop breast cancer in their lifetime in the United States ([@b1-ol-0-0-11406],[@b2-ol-0-0-11406]). Breast cancer is commonly divided into two types: Infiltrating lobular carcinoma, which originates in the cells of the lobules, and infiltrating ductal carcinoma, which originates in the ducts ([@b2-ol-0-0-11406]). A few subtypes originate in the stromal tissues, such as the fatty and fibrous connective tissues of the breast. There are four molecular subtypes of breast cancer, according to the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67, including luminal A, luminal B, HER2-enriched and basal-like ([@b2-ol-0-0-11406]). The pathogenesis of breast cancer remains unclear; however, it is considered to begin with alterations at the genomic level ([@b2-ol-0-0-11406]). Different types of breast cancer have a wide range of tumor growth rates and variable clinical courses, thus potential biomarkers are required to aid with diagnosis and prognosis, and may also function as novel targets in the treatment of breast cancer.

Interferon-stimulated gene 15 (ISG15) is the first ubiquitin-like protein to be discovered and reported as a negative regulator in IFN-α/β immunity, and to play a key role in antivirus and antitumor defences ([@b3-ol-0-0-11406],[@b4-ol-0-0-11406]). ISG15 is upregulated by IFNs ([@b5-ol-0-0-11406]) and has the ability to conjugate with ubiquitin-associated proteins ([@b3-ol-0-0-11406],[@b4-ol-0-0-11406]). The conjugation process, known as interferon-stimulated gene 15 conjugation (ISGylation), includes three respective steps, namely activation, conjugation and ligation, and occurs in several cellular signaling pathways ([@b6-ol-0-0-11406]). A total of three classes of enzymes partake in this process, including an E1 activating enzyme \[ubiquitin-like modifier-activating enzyme 7 (UBA7)\], E2 conjugating enzymes, such as ubiquitin-carrier protein H8 (UBCH8) and ubiquitin-carrier protein H6 (UBCH6), and E3 ligases, such as estrogen-responsive finger protein (EFP), and HECT domain and RCC1-like domain-containing protein 5 (HERC5) ([@b7-ol-0-0-11406]). Currently, UBA7 is the only known E1-activating enzyme ([@b8-ol-0-0-11406]), and ISGylation has the ability to both activate and inhibit the activity of target proteins ([@b4-ol-0-0-11406]).

UBA7, also referred to as ubiquitin-activating enzyme E1-like protein (UBE1L), is the specific E1-like ubiquitin-activating enzyme that functions in ISGylation ([@b9-ol-0-0-11406]). Currently, the only known biological function of UBA7 is catalysing ISGylation. Both type I IFN and retinoic acid can induce UBA7 expression ([@b10-ol-0-0-11406]). Most previous studies on the UBA7/ISG15 signaling pathway in cancer have focused on lung cancer ([@b8-ol-0-0-11406]--[@b12-ol-0-0-11406]). UBA7 is located on chromosome 3p21.3 and is considered to be a candidate tumor suppressor gene. The loss of allelic heterozygosity (LOH) on 3p21.3 has been observed in 70--80% of non-small cell lung cancer (NSCLC) and 90--100% of SCLC cases ([@b8-ol-0-0-11406]). Furthermore, UBA7 expression was demonstrated to be notably decreased in several lung cancer cell lines ([@b11-ol-0-0-11406]). A number of studies have indicated that UBA7 suppresses tumor growth by inhibiting cyclin D1 expression, and that it can downregulate epidermal growth factor receptor (EGFR) expression in human bronchial epithelial cells ([@b9-ol-0-0-11406],[@b12-ol-0-0-11406]). However, to the best of our knowledge, there are currently no studies on the change in UBA7 expression in breast cancer. Thus, the present study set out to determine whether UBA7 could function as a biomarker in breast cancer.

The present study evaluated UBA7 expression in breast cancer, while subtypes were also taken into consideration, and the potential association between UBA7 expression and clinical characteristics was analyzed. The efficiency of UBA7 expression in diagnosis was also assessed, along with its prognostic value using overall survival (OS) and relapse-free survival (RFS) as outcome measures.

Materials and methods
=====================

### Data collection

The clinical data and RNA-sequencing (RNA-seq) expression values of patients with breast cancer were downloaded from The Cancer Genome Atlas (TCGA) database (<https://cancergenome.nih.gov/>), and the corresponding accession code was TCGA-BRCA. The RNA-seq by expectation-maximization expression values were used in the statistical analysis of RNA-seq data.

### Statistical analysis

R software (version 3.5.2) and associated packages were used for data analysis ([@b13-ol-0-0-11406],[@b14-ol-0-0-11406]). Wilcoxon test, Kruskal Wallis test and Dunn\'s post-hoc test were used in this study. mRNA expression differences between groups of discrete variables were depicted as boxplots generated by the ggplot2 package (version 3.2.1) in R software, and the association between clinical characteristics and UBA7 expression was assessed using χ^2^ and Fisher\'s exact tests. A receiver operating characteristic (ROC) curve generated by the pROC package (version 1.15.3) in R software was used to determine the diagnostic capability of UBA7. UBA7 expression levels were divided into low and high groups, according to the optimal cut-off value, as determined by OS analysis using the ROC curve. Kaplan-Meier curves were generated to compare OS and RFS between the low and high expression groups, and P-values were calculated using the log-rank test. Univariate Cox analysis was performed to select the variables associated with OS and RFS, and multivariate Cox analysis was performed to assess the effect of UBA7 expression on survival and other clinical characteristics. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

Both the clinical data and RNA-seq expression data of 1,104 patients with breast cancer were downloaded from TCGA database. The detailed clinical characteristics, including molecular subtype, Tumor-Node-Metastasis stage ([@b2-ol-0-0-11406]), residual tumor status, survival status and therapy type, are presented in [Table I](#tI-ol-0-0-11406){ref-type="table"}.

Association between UBA7 expression and clinicopathological characteristics. Low UBA7 mRNA expression levels were observed in breast cancer tissues compared with those in normal tissues from the same patients (P=0.039; [Fig. 1A](#f1-ol-0-0-11406){ref-type="fig"}). Significant differences in UBA7 expression were also demonstrated according to: Vital status (P=2.1×10^−4^), T classification (P=0.025), M classification (P=0.0003), histological type (P=1.6×10^−13^) and sex (P=0.016) ([Fig. 1](#f1-ol-0-0-11406){ref-type="fig"}). Furthermore, UBA7 expression was indicated to be significantly associated with the expression of breast cancer-associated molecules, as determined by the molecular subtype of breast cancer (P=4.1×10^−11^; [Fig. 2A](#f2-ol-0-0-11406){ref-type="fig"}), and the expression of PR (P=8.3×10^−12^; [Fig. 2B](#f2-ol-0-0-11406){ref-type="fig"}), ER (P=1.2×10^−7^; [Fig. 2C](#f2-ol-0-0-11406){ref-type="fig"}) and HER2 (P=0.0089; [Fig. 2D](#f2-ol-0-0-11406){ref-type="fig"}). However, no significant associations were demonstrated between UBA7 expression and the use of radiation therapy (P=0.43; [Fig. 2E](#f2-ol-0-0-11406){ref-type="fig"}), neoadjuvant therapy (P=0.11; [Fig. 2F](#f2-ol-0-0-11406){ref-type="fig"}) or targeted molecular therapy (P=0.92; [Fig. 2G](#f2-ol-0-0-11406){ref-type="fig"}).

UBA7 expression was divided into high and low groups according to the cutoff point (9.542), and low UBA7 level was demonstrated to be associated with histological type (P=0.0005), molecular subtype (P=0.0005), and the expression of ER (P=0.0005), PR (P=0.0005) and HER2 (P=0.0185), M classification (P=0.0090), vital status (P=0.0005), OS (P=0.0005) and RFS (P=0.0005; [Table II](#tII-ol-0-0-11406){ref-type="table"}).

### Diagnostic capability of UBA7

ROC curves were generated to determine the diagnostic ability of UBA7 in breast cancer ([Fig. 3](#f3-ol-0-0-11406){ref-type="fig"}). The area under the curve (AUC) value was 0.559 ([Fig. 3A](#f3-ol-0-0-11406){ref-type="fig"}), which indicates a reasonable diagnostic ability. Subsequently, subgroup analysis of different stages was performed and all data presented an adequate diagnostic ability (0.540 for stage I, 0.562 for stage II, 0.557 for stage III and 0.551 for stage IV; [Fig. 3B-E](#f3-ol-0-0-11406){ref-type="fig"}).

### Low UBA7 expression is associated with poor survival

Kaplan-Meier curves were generated and a log-rank test was performed to evaluate the prognostic value of UBA7 in breast cancer, and OS and RFS were used as prognostic parameters. The results demonstrated that patients with low UBA7 expression levels had poorer OS (P\<0.0001; [Fig. 4A](#f4-ol-0-0-11406){ref-type="fig"}). Further molecular subtype analysis demonstrated that patients with luminal A breast cancer (P=0.0210; [Fig. 4B](#f4-ol-0-0-11406){ref-type="fig"}), luminal B breast cancer (P=0.0054; [Fig. 4C](#f4-ol-0-0-11406){ref-type="fig"}), infiltrating ductal carcinoma (P=1.4×10^−4^; [Fig. 4F](#f4-ol-0-0-11406){ref-type="fig"}) or infiltrating lobular carcinoma (P=0.0033; [Fig. 4G](#f4-ol-0-0-11406){ref-type="fig"}) had poorer OS in the presence of low UBA7 expression. Univariate Cox analysis identified the critical variables associated with OS, including age (P\<0.001), HER2 expression (P=0.0130), stage (P\<0.001), margin status (P=0.0050) and UBA7 expression (P\<0.001) ([Table III](#tIII-ol-0-0-11406){ref-type="table"}). Multivariate Cox analysis indicated that age \[hazard ratio (HR), 2.31; P\<0.001), stage (HR, 2.12; P\<0.001) and UBA7 expression (HR, 2.10; P=0.0020) may serve as independent prognostic factors, as presented in [Table III](#tIII-ol-0-0-11406){ref-type="table"}.

Patients with low UBA7 expression levels also had a poor prognosis in terms of RFS (P=0.0011; [Fig. 5A](#f5-ol-0-0-11406){ref-type="fig"}). Furthermore, low UBA7 expression was associated with poor RFS in patients with luminal B breast cancer (P\<0.0001; [Fig. 5C](#f5-ol-0-0-11406){ref-type="fig"}), infiltrating ductal carcinoma (P=0.0031; [Fig. 5F](#f5-ol-0-0-11406){ref-type="fig"}) and infiltrating lobular carcinoma (P=0.0310; [Fig. 5G](#f5-ol-0-0-11406){ref-type="fig"}). Univariate Cox analysis and multivariate Cox analysis indicated that stage (P\<0.001), margin status (P=0.0050) and UBA7 expression (P=0.0370) were independent prognostic factors for poor RFS ([Table IV](#tIV-ol-0-0-11406){ref-type="table"}).

Kaplan-Meier curves were generated using the log-rank test to further investigate the association between UBA7 expression and the expression levels of ER, PR and HER2 in terms of OS ([Fig. 6](#f6-ol-0-0-11406){ref-type="fig"}) and RFS ([Fig. 7](#f7-ol-0-0-11406){ref-type="fig"}). The results demonstrated patients with ER-positive (P=1.8×10^−4^; [Fig. 6B](#f6-ol-0-0-11406){ref-type="fig"}). PR-negative (P=0.0180; [Fig. 6C](#f6-ol-0-0-11406){ref-type="fig"}), PR-positive (P=0.0031; [Fig. 6D](#f6-ol-0-0-11406){ref-type="fig"}) and HER2-negative (P=0.0180; [Fig. 6E](#f6-ol-0-0-11406){ref-type="fig"}) breast cancer had poor OS in the presence of low UBA7 expression. Furthermore, patients with ER-positive (P=0.0066; [Fig. 7B](#f7-ol-0-0-11406){ref-type="fig"}) and PR-negative (P=0.0350; [Fig. 7C](#f7-ol-0-0-11406){ref-type="fig"}) breast cancer also had poor RFS in the presence of low UBA7 expression.

Discussion
==========

Previous studies have set out to identify novel biomarkers for the diagnosis and prognosis of different diseases ([@b15-ol-0-0-11406]--[@b24-ol-0-0-11406]); however, to the best of our knowledge, the present study was the first to demonstrate that UBA7 may function as a biomarker in breast cancer. The results demonstrated that UBA7 expression was decreased in breast cancer compared with that in normal tissues. Furthermore, UBA7 expression differences were associated with vital status, tumor classification, metastasis classification, histological type, sex, molecular subtype, and the expression of PR, ER and HER2. The low and high UBA7 expression groups also demonstrated differences in some clinical characteristics, including molecular subtype, histological subtype and expression of ER, PR and HER2, vital status, OS and RFS. Patients with lower UBA7 expression had a poor prognosis. Although UBA7 demonstrated a reasonable diagnostic capability, it may still be used in combination with other markers to diagnose breast cancer.

Currently, the only known biological function of UBA7 is catalysing ISG15 conjugation. Previous studies have reported that UBA7 has the potential to act as a tumor suppressor gene in human lung cancer ([@b8-ol-0-0-11406]--[@b12-ol-0-0-11406]). UBA7 is located on human chromosome region 3p21.3, and LOH on chromosome 3p21.3 has been observed in 70--80% of NSCLC and 90--100% of SCLC cases ([@b8-ol-0-0-11406]). The expression levels of UBA7, previously referred to as UBE1L, have been reported to be markedly decreased in several lung cancer cell lines ([@b11-ol-0-0-11406],[@b25-ol-0-0-11406],[@b26-ol-0-0-11406]). Notably, Kok *et al* ([@b27-ol-0-0-11406]) demonstrated that although one allele of UBA7 was absent in lung cancer cell lines, the remaining allele was still detectable and without mutation ([@b27-ol-0-0-11406]). The results of the present study demonstrated that UBA7 expression was significantly decreased in breast cancer and that stage IV tumors had the lowest UBA7 expression levels. Furthermore, UBA7 expression was also associated with clinical characteristics, and low UBA7 expression was demonstrated to be associated with poor prognosis, especially in patients with ER-positive and PR-positive breast cancer.

A number of studies have demonstrated that UBA7 can promote the formation of a complex between ISG15 and cyclin D1, and inhibit cyclin D1, which is associated with cancer cell proliferation ([@b8-ol-0-0-11406]--[@b12-ol-0-0-11406]). UBA7-knockdown has been reported to increase cyclin D1 expression; however, overexpression of UBA7 has been shown to reduce cyclin D1 expression and suppress lung cancer cell proliferation ([@b9-ol-0-0-11406]). Furthermore, it has been reported that UBA7 can suppress EGFR at the post-translational level in HBE-Beas-2B cells and suppress the subsequent AKT/NF-κB signaling pathway ([@b12-ol-0-0-11406]). However, deficiency of UBA7 has no effect in K-ras (LA2)-mutant mice with lung cancer, thus UBA7 is not considered a tumor suppressor gene in the K-ras lung cancer mouse model ([@b8-ol-0-0-11406]). In the present study, the decreased UBA7 expression levels in breast cancer were not as obvious as it was demonstrated to be in lung cancer, thus it is suggested that UBA7 may not have the same effect on breast cancer cells. Furthermore, the results of the present study demonstrated that UBA7 was associated with the expression of PR, ER and HER2, and the molecular subtypes of breast cancer, thus UBA7 may have the potential to influence the proliferation of breast cancer cells through these molecules, which are closely associated with breast cancer. The association between UBA7 expression and cyclin D1, EGFR, ER, PR, HER2 and other tumor-associated molecules requires further experimental evidence; however, UBA7 may function as a target in treatment according to current data on lung cancer.

The molecular mechanism underlying UBA7 regulation remains unclear; however, a number of molecules have been reported to influence UBA7 expression. For example, IFN-α has the ability to induce ISGylation-associated protein expression, including UBA7 expression ([@b28-ol-0-0-11406]). Furthermore, retinoic acid has been demonstrated to induce UBA7 expression, which in turn induces ISGylation of promyelocytic leukaemia/retinoic acid receptor-α protein and causes degradation in acute promyelocytic leukaemia ([@b29-ol-0-0-11406]). Previous studies have reported that chemopreventive polyphenols ([@b10-ol-0-0-11406],[@b30-ol-0-0-11406],[@b31-ol-0-0-11406]), such as curcumin, epigallocatechin gallate and resveratrol, have the ability to influence UBA7 expression by altering the intracellular reactive oxygen species status, which is regulated via the c-Jun N-terminal kinase/nuclear factor erythroid 2-related factor 2 signaling pathway; however, this association exhibits dose-dependent effects ([@b10-ol-0-0-11406]). IFNs have been used with the intent to cure cancer for several years, including breast cancer ([@b30-ol-0-0-11406]). IFNs have been reported to exert antitumor effects by regulating the immune system and affecting cell proliferation and apoptosis ([@b31-ol-0-0-11406]). A limitation of the present study was failure to assess the influence of IFNs on UBA7 expression. Thus, future studies will focus on the use of IFNs and other molecules, including chemopreventive polyphenols, which may influence UBA7 expression, while studying the change in UBA7 expression in breast cancer, and will aim to investigate whether IFNs suppress breast cancer through the UBA7 pathway.

Although UBA7 has been considered a potential tumor suppressor gene in lung cancer for decades, its underlying molecular mechanism still remains unclear. Furthermore, the role of UBA7 in different types of cancer still lacks sufficient evidence to support this hypothesis. To the best of our knowledge, the present study was the first to uncover UBA7 expression changes in breast cancer. The results demonstrated that UBA7 expression was decreased in breast cancer and was also associated with clinical characteristics. In addition, low UBA7 expression was associated with a poor prognosis. Taken together, these results suggest that UBA7 may function as a biomarker for the clinical diagnosis and prognosis of breast cancer, and even as a target in treatment.

The present study aimed to identify the changes in UBA7 expression in breast cancer using bioinformatic methods from a macro perspective. Further studies and evidence from the laboratory are required to support the stated speculations, and the potential molecular mechanisms also need to be investigated. The subsequent stages of research have already been designed, and will focus on laboratory work, including the collection of tissues from patients, analysis of UBA7 and other related molecules expression levels in tissues, and the exploration of associations between molecules and clinical features, and even potential molecular mechanisms using cells.
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![Differences in UBA7 expression according to clinicopathological characteristics. (A) UBA7 expression was lower in breast cancer tissues compared with that in normal tissues. Expression was significantly associated with (C) vital status, (D) tumor classification, (F) metastasis classification, (I) histological type and (K) gender. However, no significant association was observed with regard to (B) clinical stage, (E) N classification, (G) lymph node status, (H) margin status, (J) sample type and (L) age. UBA7, ubiquitin-like modifier-activating enzyme 7; T, tumor; M, metastasis.](ol-19-04-2773-g00){#f1-ol-0-0-11406}

![Differences in UBA7 expression according to clinicopathological characteristics. Significant differences were observed according to (A) molecular subtype of breast cancer, and (B) PR, (C) ER and (D) HER2 expression. However, no significant differences were observed according to (E) radiation therapy, (F) neoadjuvant treatment and (G) targeted molecular therapy. UBA7, ubiquitin-like modifier-activating enzyme 7; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.](ol-19-04-2773-g01){#f2-ol-0-0-11406}

![Receiver operating characteristic curves of UBA7 in different clinical stages. UBA7 exhibited mild diagnostic ability. (A) The AUC is 0.559, which represents a reasonable diagnostic ability. (B-E) Subgroup analysis of different stages also demonstrated a reasonable diagnostic ability. UBA7, ubiquitin-like modifier-activating enzyme 7; AUC, area under the curve.](ol-19-04-2773-g02){#f3-ol-0-0-11406}

![Analysis of the association between UBA7 expression and OS. (A) Patients with low UBA7 expression had poor OS. Patients with (B) Luminal A breast cancer, (C) Luminal B breast cancer, (F) infiltrating ductal carcinoma and (G) infiltrating lobular carcinoma had poor OS in the presence of low UBA7 expression. However, no significant associations were observed between UBA7 expression and OS in patients with (D) HER2-enriched breast cancer and (E) basal-like breast cancer, and in (H) normal cases. UBA7, ubiquitin-like modifier-activating enzyme 7; OS, overall survival; HER2, human epidermal growth factor receptor 2.](ol-19-04-2773-g03){#f4-ol-0-0-11406}

![Survival analysis of UBA7 expression in terms of RFS. (A) Patients with low UBA7 expression had a poor prognosis in terms of RFS. Low UBA7 expression was significantly associated with poor RFS in patients with (C) Luminal B breast cancer, (F) infiltrating ductal carcinoma and (G) infiltrating lobular carcinoma. However, no significant associations were observed between UBA7 expression and RFS in patients with (B) Luminal A breast cancer, (D) HER2-enriched breast cancer and (E) basal-like breast cancer, and in (H) normal cases. UBA7, ubiquitin-like modifier-activating enzyme 7; RFS, relapse-free survival; HER2, human epidermal growth factor receptor 2.](ol-19-04-2773-g04){#f5-ol-0-0-11406}

![Survival analysis of UBA7 expression in terms of OS, according to the expression of ER, PR and HER2. Low UBA7 expression was significantly associated with poor OS in (B) ER-positive, PR (C) -negative and (D) -positive, and (E) HER2-negative patients. However, no significant associations were observed between low UBA7 expression and OS in (A) ER-negative and (F) HER2-positive patients. UBA7, ubiquitin-like modifier-activating enzyme 7; OS, overall survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.](ol-19-04-2773-g05){#f6-ol-0-0-11406}

![Survival analysis of UBA7 expression in terms of RFS, according to the expression of ER, PR and HER2. Low UBA7 expression was significantly associated with poor RFS in (B) ER-positive and (C) PR-negative patients. However, no significant associations were observed between low UBA7 expression and RFS in (A) ER-negative, (D) PR-positive, and HER2 (E) -negative and (F) -positive patients. UBA7, ubiquitin-like modifier-activating enzyme 7; RFS, relapse-free survival; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.](ol-19-04-2773-g06){#f7-ol-0-0-11406}

###### 

Clinical patient characteristics.

  Characteristics                    Number of cases (%)
  ---------------------------------- ---------------------
  Age, years                         
    \<60                             590 (53.44)
    ≥60                              514 (46.56)
  Sex                                
    N/A                              2 (0.18)
    Female                           1090 (98.73)
    Male                             12 (1.09)
    Histological type                
    N/A                              3 (0.27)
    Infiltrating ductal carcinoma    790 (71.56)
    Infiltrating lobular carcinoma   204 (18.48)
    Other                            107 (9.69)
  Molecular subtype                  
    N/A                              255 (23.04)
    Basal                            142 (12.86)
    HER2-enriched                    67 (6.07)
    Luminal A                        422 (38.22)
    Luminal B                        194 (17.57)
    Normal                           24 (2.17)
  ER status                          
    N/A                              50 (4.53)
    Indeterminate                    2 (0.18)
    Negative                         239 (21.65)
    Positive                         813 (73.64)
  PR status                          
    N/A                              51 (4.62)
    Indeterminate                    4 (0.36)
    Negative                         345 (31.25)
    Positive                         704 (63.77)
  HER2 status                        
    N/A                              183 (16.58)
    Equivocal                        180 (16.3)
    Indeterminate                    12 (1.09)
    Negative                         565 (51.18)
    Positive                         164 (14.86)
  Menopause status                   
    N/A                              93 (8.42)
    Indeterminate                    34 (3.08)
    Peri                             40 (3.62)
    Post                             706 (63.95)
    Pre                              231 (20.92)
  T classification                   
    N/A                              2 (0.18)
    T1                               281 (25.45)
    T2                               640 (57.97)
    T3                               138 (12.50)
    T4                               40 (3.62)
    TX                               3 (0.27)
  N classification                   
    N/A                              2 (0.18)
    N0                               516 (46.74)
    N1                               367 (33.24)
    N2                               120 (10.87)
    N3                               79 (7.16)
    NX                               20 (1.81)
  M classification                   
    N/A                              2 (0.18)
    M0                               917 (83.06)
    M1                               22 (1.99)
    MX                               163 (14.76)
  Stage                              
    N/A                              10 (0.91)
    I                                182 (16.49)
    II                               626 (56.70)
    III                              252 (22.83)
    IV                               20 (1.81)
    X                                14 (1.27)
  Lymph node status                  
    N/A                              379 (34.33)
    No                               28 (2.54)
    Yes                              697 (63.13)
  Margin status                      
    N/A                              72 (6.52)
    Close                            31 (2.81)
    Negative                         922 (83.51)
    Positive                         79 (7.16)
  Vital status                       
    N/A                              2 (0.18)
    Deceased                         155 (14.04)
    Living                           947 (85.78)
  Radiation therapy                  
    N/A                              102 (9.24)
    No                               445 (40.31)
    Yes                              557 (50.45)
  Neoadjuvant treatment              
    N/A                              3 (0.27)
    No                               1088 (98.55)
    Yes                              13 (1.18)
  Targeted molecular therapy         
    N/A                              525 (47.55)
    No                               46 (4.17)
    Yes                              533 (48.28)
  Sample type                        
    Metastatic                       7 (0.63)
    Primary tumor                    1097 (99.37)
  Overall survival                   
    N/A                              17 (1.53)
    No                               933 (84.51)
    Yes                              154 (13.95)
  Relapse-free survival              
    N/A                              192 (17.39)
    No                               816 (73.91)
    Yes                              96 (8.70)
  UBA7                               
    High                             588 (53.26)
    Low                              516 (46.74)

N/A, not available; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; UBA7, ubiquitin-like modifier-activating enzyme 7.

###### 

Association between UBA7 mRNA expression and clinicopathological characteristics in patients with breast cancer.

                                            UBA7 mRNA expression                             
  ---------------------------------- ------ ---------------------- ------------- ----------- ------------------------------------------------------
  Age, years                                                                     2.9564      0.0830
    \<60                             589    299 (51.02)            290 (56.2)                
    ≥60                              513    287 (48.98)            226 (43.8)                
  Sex                                                                            3.8682      0.0785
    Female                           1090   583 (99.49)            507 (98.26)               
    Male                             12     3 (0.51)               9 (1.74)                  
  Histological type                                                              43.5504     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    Infiltrating ductal carcinoma    790    377 (64.33)            413 (80.19)               
    Infiltrating lobular carcinoma   204    150 (25.6)             54 (10.49)                
    Other                            107    59 (10.07)             48 (9.32)                 
  Molecular subtype                                                              37.2883     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    Basal                            142    44 (11.11)             98 (21.63)                
    HER2-enriched                    67     26 (6.57)              41 (9.05)                 
    Luminal A                        422    237 (59.85)            185 (40.84)               
    Luminal B                        194    75 (18.94)             119 (26.27)               
    Normal                           24     14 (3.54)              10 (2.21)                 
  ER status                                                                      17.7115     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    Indeterminate                    2      1 (0.18)               1 (0.2)                   
    Negative                         239    98 (17.56)             141 (28.43)               
    Positive                         813    459 (82.26)            354 (71.37)               
  PR status                                                                      30.3951     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    Indeterminate                    4      2 (0.36)               2 (0.4)                   
    Negative                         345    141 (25.27)            204 (41.21)               
    Positive                         704    415 (74.37)            289 (58.38)               
  HER2 status                                                                    10.4688     0.0185^[b](#tfn3-ol-0-0-11406){ref-type="table-fn"}^
    Equivocal                        180    90 (18.95)             90 (20.18)                
    Indeterminate                    12     9 (1.89)               3 (0.67)                  
    Negative                         565    307 (64.63)            258 (57.85)               
    Positive                         164    69 (14.53)             95 (21.3)                 
  Menopause status                                                               5.2218      0.1549
    Indeterminate                    34     14 (2.61)              20 (4.22)                 
    Peri                             40     21 (3.91)                            19 (4.01)   
    Post                             706    390 (72.63)            316 (66.67)               
    Pre                              231    112 (20.86)            119 (25.11)               
  T classification                                                               7.3029      0.1014
    T1                               281    163 (27.82)            118 (22.87)               
    T2                               640    321 (54.78)            319 (61.82)               
    T3                               138    81 (13.82)             57 (11.05)                
    T4                               40     20 (3.41)              20 (3.88)                 
    TX                               3      1 (0.17)               2 (0.39)                  
  N classification                                                               8.1021      0.0985
    N0                               516    284 (48.46)            232 (44.96)               
    N1                               367    196 (33.45)            171 (33.14)               
    N2                               120    53 (9.04)              67 (12.98)                
    N3                               79     46 (7.85)              33 (6.4)                  
    NX                               20     7 (1.19)               13 (2.52)                 
  M classification                                                               8.9899      0.0090^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    M0                               917    472 (80.55)            445 (86.24)               
    M1                               22     10 (1.71)              12 (2.33)                 
    MX                               163    104 (17.75)            59 (11.43)                
  Stage                                                                          6.3959      0.1714
    I                                182    106 (18.24)            76 (14.81)                
    II                               626    334 (57.49)            292 (56.92)               
    III                              252    128 (22.03)            124 (24.17)               
    IV                               20     9 (1.55)               11 (2.14)                 
    X                                14     4 (0.69)               10 (1.95)                 
  Lymph node status                                                              0.0215      1.0000
    No                               28     16 (3.77)              12 (3.99)                 
    Yes                              697    408 (96.23)            289 (96.01)               
  Margin status                                                                  0.4795      0.7816
    Close                            31     15 (2.7)               16 (3.35)                 
    Negative                         922    496 (89.37)            426 (89.31)               
    Positive                         79     44 (7.93)              35 (7.34)                 
  Vital status                                                                   19.4879     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    Deceased                         155    57 (9.73)              98 (18.99)                
    Living                           947    529 (90.27)            418 (81.01)               
  Radiation therapy                                                              0.0058      0.9535
    No                               445    241 (44.3)             204 (44.54)               
    Yes                              557    303 (55.7)             254 (55.46)               
  Neoadjuvant treatment                                                          2.9898      0.0925
    No                               1088   575 (98.29)            513 (99.42)               
    Yes                              13     10 (1.71)              3 (0.58)                  
  Targeted therapy                                                               0.1257      0.7571
    No                               46     23 (8.36)              23 (7.57)                 
    Yes                              533    252 (91.64)            281 (92.43)               
  Sample type                                                                    0.9341      0.4663
    Metastatic                       7      5 (0.85)               2 (0.39)                  
    Primary tumor                    1097   583 (99.15)            514 (99.61)               
  Overall survival                                                               19.9101     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    No                               933    520 (90.28)            413 (80.82)               
    Yes                              154    56 (9.72)              98 (19.18)                
  Relapse-free survival                                                          10.6443     0.0005^[a](#tfn2-ol-0-0-11406){ref-type="table-fn"}^
    No                               816    474 (92.4)             342 (85.71)               
    Yes                              96     39 (7.6)               57 (14.29)                

P\<0.01

P\<0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; UBA7, ubiquitin-like modifier-activating enzyme 7.

###### 

Univariate and multivariate analyses of overall survival in patients with breast cancer.

                      Univariate analysis   Multivariate analysis                                                                               
  ------------------- --------------------- ----------------------- ------------------------------------------------------- ------ ------------ -------------------------------------------------------
  Age, years          1.91                  1.39--2.63              \<0.001^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^   2.31   1.44--3.68   \<0.001^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^
  Histological type   0.93                  0.74--1.17              0.543                                                                       
  Molecular subtype   1.01                  0.88--1.16              0.901                                                                       
  ER                  0.85                  0.71--1.02              0.074                                                                       
  PR                  0.87                  0.73--1.03              0.096                                                                       
  HER2                1.29                  1.05--1.57              0.013^[b](#tfn5-ol-0-0-11406){ref-type="table-fn"}^     1.10   0.88--1.37   0.3840
  Menopause status    1.16                  0.94--1.43              0.165                                                                       
  Stage               1.64                  1.40--1.91              \<0.001^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^   2.12   1.60--2.80   \<0.001^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^
  Lymph node status   1.10                  0.93--1.30              0.274                                                                       
  Margin status       1.42                  1.11--1.81              0.005^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^     0.98   0.70--1.38   0.9290
  UBA7                2.09                  1.50--2.90              \<0.001^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^   2.10   1.30--3.39   0.0020^[a](#tfn4-ol-0-0-11406){ref-type="table-fn"}^

P\<0.01

P\<0.05. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; UBA7, ubiquitin-like modifier-activating enzyme 7.

###### 

Univariate and multivariate analyses of relapse-free survival in patients with breast cancer.

                      Univariate analysis   Multivariate analysis                                                                               
  ------------------- --------------------- ----------------------- ------------------------------------------------------- ------ ------------ -------------------------------------------------------
  Age, years          1.45                  0.97--2.16              0.072                                                                       
  Histological type   0.86                  0.65--1.14              0.290                                                                       
  Molecular subtype   0.99                  0.82--1.20              0.945                                                                       
    ER                0.78                  0.63--0.97              0.026^[a](#tfn6-ol-0-0-11406){ref-type="table-fn"}^     0.88   0.63--1.22   0.441
    PR                0.78                  0.64--0.96              0.019^[a](#tfn6-ol-0-0-11406){ref-type="table-fn"}^     0.87   0.64--1.18   0.360
    HER2              0.93                  0.70--1.22              0.596                                                                       
  Menopause status    0.95                  0.74--1.22              0.713                                                                       
  Stage               1.71                  1.40--2.08              \<0.001^[b](#tfn7-ol-0-0-11406){ref-type="table-fn"}^   1.55   1.24--1.92   \<0.001^[b](#tfn7-ol-0-0-11406){ref-type="table-fn"}^
  Lymph node status   0.86                  0.70--1.06              0.159                                                                       
  Margin status       1.59                  1.23--2.06              \<0.001^[b](#tfn7-ol-0-0-11406){ref-type="table-fn"}^   1.48   1.13--1.94   0.005^[b](#tfn7-ol-0-0-11406){ref-type="table-fn"}^
  UBA7                1.95                  1.30--2.93              0.001^[b](#tfn7-ol-0-0-11406){ref-type="table-fn"}^     1.59   1.03--2.45   0.037^[a](#tfn6-ol-0-0-11406){ref-type="table-fn"}^

P\<0.05

P\<0.01. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; UBA7, ubiquitin-like modifier-activating enzyme.
